Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Biomarker testing may transform treatment of acute GVHD

Key clinical point: Two biomarkers, ST2 and REG3-alpha, can be used to predict nonrelapse mortality in patients with acute graft-versus-host disease (GVHD).

Major finding: The biomarkers, assessed after 1 week or 1 month of therapy, predicted 6-month nonrelapse mortality more accurately than clinical response assessed at 1 month (P less than .001 for both time points).

Study details: A prospective study of 355 patients with acute graft-versus-host disease.

Disclosures: The research was supported by grants from the National Cancer Institute and the American Cancer Society. Dr. Ferrara reported having an ownership interest in and royalties from Viracor, the company that bought the rights to the biomarker testing.

Citation:

REPORTING FROM ALF 2019